This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Malcolm S. Artenstein, MD
Walter Reed Army Medical Center Washington, DC

JAMA. 1975;234(2):151.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

Dr Eickhoff presents a cogent argument for the use of rifampin prophylaxis when meningococcal disease has been diagnosed in one member of a family. Indeed, a number of authorities hold the same opinion. However, in the absence of proved (controlled) efficacy of the drug in preventing meningococcal disease, the controversy becomes merely a matter of divergent opinions based on circumstantial evidence. Minocycline was the choice of some until the recent reports of serious side reactions. I am tempted to predict, therefore, that rifampin, which has immunosuppressive effects and inhibits RNA and DNA polymerases, will eventually be considered too hazardous a drug to be used for a purpose of unproved benefit. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?